BLIS Technologies Limited · NZX:BLT
BLIS Technologies — Shareholder Meeting (March 2009)
11 slides from BLIS Technologies's shareholder meeting presentation, Mar 31, 2009
Slide 1: BLIS Technologies Ltd Shareholder Update
BLIS Technologies Ltd Shareholder Update 31 March 2009 Barry Richardson Chief Executive Officer
Slide 2: BLIS Financials
BLIS Financials •Highest priority is positive cash flow. Have invested in US market development to build sales. •Sales increasing in the US but NZ & Australian sales have fallen significantly. Irish sales slow - coupled with initial labelling issues. • BLIS costs well controlled and known (opex ~ $1
Slide 3: News
News • BLIS has signed distribution and marketing agreement in Korea with a pharmaceutical company for finished products - seeking regulatory approval. • BLIS has signed distribution and marketing agreement in China for finished products with NZ Co. operating in China and partner, wholly owned by Pr
Slide 4: Strategic Update
Strategic Update • BLIS is implementing its global business strategy – primarily BLIS K12 ingredient sales. • Nestle Nutrition: Licensing & option agreement - clinical study proceeding; anticipate completion in 2010. • Oct 08: BLIS appoints Frutarom as global distributor of ingredients. Strategy is
Slide 5: Sales & Marketing Update
Sales & Marketing Update • Technical advances made in the last 2 years enable BLIS to enter international markets. • BLIS is providing Frutarom with technical marketing support for BLIS K12 ingredient – redefines role in ingredient sales. • Good progress with marketing projects in Japan, China, Kore
Slide 6: New US Product Applications
New US Product Applications Product Format Use Lozenge, Healthy throat, fresh mint flavored breath Product Applications Chewable tablet, Pediatric ear support, combination of BLIS prevention of ear K12 and gut probiotic infections
Slide 7: Product Format Use
Product Format Use Lozenge, Adults Ear, Nose & cherry flavored Throat
Slide 8: Operations & Development Update
Operations & Development Update • K12 production in NZ; transferring technology for BLIS K12 to US company to achieve commercial volume. • India: Agreement with Tablets India to produce Finished products. Investigating other options. • Leading edge technological advances in stability and oral persis
Slide 9: Regulatory Update
Regulatory Update • Regulatory approval is the major barrier to market entry in some regions. • FSANZ consider K12 is not a NOVEL FOOD. • Some finished products already approved in Europe (Ireland, Germany, Spain). • Approval being sought in China and Korea. Limited sales opportunities in some other
Slide 10: Key Tasks
Key Tasks Financial: • Achieve positive cash flow and conserve cash assets. Sales & Marketing: • Meet forecast sales in priority markets (US, Australia, Europe & Asia). Commence sales in markets requiring regulatory approval. • Manage wide range of marketing projects, building relationships globally
Slide 11: Rights Issue
Rights Issue • Underwritten by Edinburgh Equity Nominees Ltd. to $3M. • Issue $1 Preference share/45 shares. • 3 year 10% coupon - converts to ordinary shares at max of 4cps. • Option of oversubscription by shareholders. Use of funds: • Major requirements - working capital, business development and